Elranatamab with daratumumab for previously treated myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies elranatamab (alone and combined with daratumumab) in people with multiple myeloma who have already received other treatments, including lenalidomide. It aims to see how well these medicines control the cancer and what side effects people experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of multiple myeloma (not a milder form like smoldering myeloma).
- Your multiple myeloma has measurable disease based on blood or urine protein levels.
- You previously received multiple myeloma treatment that included lenalidomide.
- You are well enough to do daily activities (ECOG score of 0 to 2).
- Any side effects from prior treatments are mostly gone (back to baseline or grade 1 or less).
- You are not pregnant and can use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
This trial compares two treatments for newly diagnosed multiple myeloma patients who are not eligible for or have delayed stem cell transplant. One group gets elranatamab plus a light version of RVd (lenalidomide, bortezomib, dexamethasone), and the other gets daratumumab plus the same light RVd. The goal is to find which combination works better.
This study tests a new drug called elranatamab for people with multiple myeloma that has come back or not responded to previous treatments. Elranatamab is a type of immunotherapy that targets a protein on myeloma cells to help your immune system fight the cancer.
This Phase 3 study compares a three-drug combination (elranatamab, daratumumab, and lenalidomide) versus a standard three-drug treatment (daratumumab, bortezomib, lenalidomide, plus dexamethasone). It aims to see which plan works better for people newly diagnosed with multiple myeloma who cannot get a stem cell transplant.
This trial tests a new combination of two drugs, elranatamab and iberdomide, for people whose multiple myeloma has returned or stopped responding to previous treatments. The goal is to see if this combination can help control the disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.